Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib with Neoadjuvant Chemotherapy in TNBC
NCT03756090Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of palbociclib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Pathological Complete Response at 1 year. Status: unknown.
02
Drugs
palbociclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03756090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03756090.